The early diagnosis of Alzheimer disease is a boon in that it enables advance planning, but that planning process can engender conflict between respect for future-oriented autonomy and future welfare.
A physician argues that pharmaceutical industry support for residency programs creates a conflict of interest and compromises the educational integrity of the programs.
Variations among physicians in diagnosis and X-ray interpretation, the percentages of which have remained essentially unchanged for five decades, raise serious ethical concerns.